Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
June 20, 2023 02:39 ET
|
Bavarian Nordic A/S
Study successfully met its primary endpoints Data from second pivotal Phase 3 study in people aged 12 to 64 years expected in the third quarter 2023 COPENHAGEN, Denmark, June 20, 2023 – Bavarian...
Bavarian Nordic rapporterer resultater fra fase 3 klinisk forsøg med VLP-baseret vaccine mod chikungunya i voksne over 65 år
June 20, 2023 02:39 ET
|
Bavarian Nordic A/S
Forsøget nåede succesfuldt sine primære endemål Resultater fra et andet afgørende fase 3 forsøg i personer i alderen 12-64 år forventes i tredje kvartal 2023 KØBENHAVN, Danmark, 20. juni 2023 –...
Bavarian Nordic rapporterer resultater for antistofresponser 12 måneder efter vaccination i fase 2-forsøg med COVID-19 boostervaccinekandidat
June 16, 2023 02:44 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 16. juni 2023– Bavarian Nordic A/S (OMX: BAVA) rapporterede i dag resultater fra en opfølgende analyse af en delmængde af forsøgspersonerne foretaget 12 måneder efter vaccination i...
Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine Candidate
June 16, 2023 02:44 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, June 16, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today the results of a 12-month follow-up analysis from a subset of subjects enrolled in a Phase 2 clinical trial of...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
June 12, 2023 12:00 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, June 12, 2023 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding...
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
June 12, 2023 12:00 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 12. juni 2023 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
May 23, 2023 12:00 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, May 23, 2023 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding...
Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer
May 23, 2023 12:00 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 23. maj 2023 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende...
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
May 23, 2023 06:14 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, May 23, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 555,430 as a consequence of employees’ exercise...
Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner
May 23, 2023 06:14 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 23. maj 2023 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har forhøjet sin aktiekapital med nominelt DKK 555.430 som følge af medarbejderes udnyttelse af...